CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Advair Diskus100/50 µg +3 moredrug
Likely dose
Advair Diskus100/50 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01907334
NCT01907334Phase 4Completed

Dose-response of Salmeterol Delivered by Advair Diskus in Children: Bioassay by Methacholine Challenge Using Oscillometry as the Endpoint

University of Florida·interventional·Posted Jul 24, 2013·Updated Oct 7, 2014

In Brief

A Phase 4 clinical trial evaluating Advair Diskus100/50 µg, Flovent Diskus 100 µg, and 2 other interventions for Asthma. Completed, enrolled 10 participants across 1 site.

Detailed Summary

To examine whether a breathing test (methacholine challenge using impulse oscillometry) can be used to tell the difference between two different doses of an inhaled drug, salmeterol, delivered by Advair in children with asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 24, 2013
Enrollment StartAug 1, 2013
Primary CompletionMay 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.9 years ago

Interventions

Advair Diskus100/50 µgdrug

Advair Diskus 100/50 µg

Flovent Diskus 100 µgdrug

Flovent Diskus 100 µg

Methacholine Chloridedrug

Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.

Albuteroldrug

Albuterol will be administered at the end of each methacholine challenge.